Net loss of Sun Pharma Advanced Research Company reported to Rs 99.65 crore in the quarter ended December 2023 as against net profit of Rs 10.15 crore during the previous quarter ended December 2022. Sales declined 89.43% to Rs 13.86 crore in the quarter ended December 2023 as against Rs 131.09 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales13.86131.09 -89 OPM %-740.4012.34 - PBDT-96.4913.28 PL PBT-99.6510.15 PL NP-99.6510.15 PL Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 5 February 2024.Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 86.42 crore in the quarter ended September 2023 as against net loss of Rs 68.40 crore during the previous quarter ended September 2022. Sales declined 32.85% to Rs 21.18 crore in the quarter ended September 2023 as against Rs 31.54 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales21.1831.54 -33 OPM %-431.87-198.48 - PBDT-83.24-65.40 -27 PBT-86.42-68.40 -26 NP-86.42-68.40 -26 Powered by Capital Market - Live News

Sun Pharma Advanced Research Company today announced that it has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors) to exclusively license SCD-153 including all patents and patent applications owned or controlled by licensors. SPARC had evaluated SCD-153 under a Material Transfer Agreement (MTA) after which it entered into an Option to License Agreement with the licensors. SPARC`s IND was approved by Drug Controller General of India (DCGI).Under the terms of the agreement, the licensors are eligible for upfront payment, milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales.Powered by Capital Market - Live News

Sun Pharma Advanced Research Company has incorporated a WOS namely SPARCLIFE Inc. in Delaware, US on 25 September 2023. The main object of the Company is to obtain the services of the WOS which would engage a team of seasoned professionals based in US who coordinates, reviews and monitors the global clinical trials being conducted through various CROs in US by the Company.Powered by Capital Market - Live News